Intra-Cellular Therapies (NASDAQ:ITCI) Price Target Increased to $100.00 by Analysts at Mizuho

Intra-Cellular Therapies (NASDAQ:ITCI) had its target price upped by Mizuho from $96.00 to $100.00 in a research report released on Friday, Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock.

ITCI has been the subject of a number of other research reports. TD Cowen lifted their price objective on shares of Intra-Cellular Therapies from $80.00 to $90.00 and gave the stock a buy rating in a report on Wednesday, April 17th. Robert W. Baird lifted their price target on shares of Intra-Cellular Therapies from $83.00 to $103.00 and gave the company an outperform rating in a report on Wednesday, April 17th. JPMorgan Chase & Co. increased their price objective on shares of Intra-Cellular Therapies from $75.00 to $78.00 and gave the stock an overweight rating in a research note on Wednesday, June 12th. Royal Bank of Canada reissued an outperform rating and issued a $86.00 target price on shares of Intra-Cellular Therapies in a report on Wednesday, April 3rd. Finally, The Goldman Sachs Group upped their target price on Intra-Cellular Therapies from $67.00 to $77.00 and gave the company a neutral rating in a report on Wednesday, April 17th. Two investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of Moderate Buy and a consensus target price of $92.67.

Intra-Cellular Therapies Stock Performance

Shares of Intra-Cellular Therapies stock opened at $76.58 on Friday. Intra-Cellular Therapies has a 1 year low of $45.50 and a 1 year high of $84.89. The firm’s 50-day simple moving average is $69.53 and its 200-day simple moving average is $68.65. The firm has a market cap of $8.08 billion, a PE ratio of -66.02 and a beta of 0.97.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.15. The firm had revenue of $144.90 million for the quarter, compared to analysts’ expectations of $141.41 million. Intra-Cellular Therapies had a negative return on equity of 18.49% and a negative net margin of 21.57%. Intra-Cellular Therapies’s revenue for the quarter was up 52.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.46) earnings per share. On average, equities analysts predict that Intra-Cellular Therapies will post -0.51 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Avoro Capital Advisors LLC bought a new position in Intra-Cellular Therapies during the 4th quarter valued at $161,543,000. Norges Bank acquired a new position in Intra-Cellular Therapies during the fourth quarter worth about $85,744,000. Avidity Partners Management LP acquired a new position in Intra-Cellular Therapies during the third quarter worth about $41,729,000. Polar Capital Holdings Plc lifted its holdings in Intra-Cellular Therapies by 150.0% in the 3rd quarter. Polar Capital Holdings Plc now owns 1,000,000 shares of the biopharmaceutical company’s stock valued at $52,090,000 after acquiring an additional 600,000 shares during the last quarter. Finally, Vanguard Group Inc. boosted its position in shares of Intra-Cellular Therapies by 6.5% during the 4th quarter. Vanguard Group Inc. now owns 9,094,302 shares of the biopharmaceutical company’s stock valued at $651,334,000 after purchasing an additional 554,577 shares in the last quarter. Institutional investors and hedge funds own 92.33% of the company’s stock.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.